Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase.
Ribavirin is a broad spectrum antiviral nucleoside that displays activity against a variety of RNA and DNA viruses. Ribavirin is currently used in combination with interferon-alpha for the treatment of hepatitis C virus (HCV) infection and was recently shown to be directly incorporated by the HCV RNA polymerase into RNA products. This capacity ultimately leads to increased mutation rates and drastically reduces the viral fitness. As a first step toward elucidating the nature of the specific interaction between ribavirin and the HCV polymerase, we have utilized fluorescence spectroscopy to monitor precisely the binding of ribavirin triphosphate (RTP) to the viral polymerase. This spectroscopic approach allowed us to clearly separate the RTP binding activity from the concomitant catalytic steps. We report here the first detailed study of the binding kinetics and thermodynamic parameters involved in the interaction between RTP and an RNA polymerase. We demonstrate that RTP binds to the same active site as nucleotides. Furthermore, we provide evidence that the HCV polymerase cannot only bind to RTP but also to nonphosphorylated ribavirin, albeit with less affinity. By using various combinations of template-primers, we also demonstrate that base pairing is not involved in the initial binding of RTP to the HCV polymerase. Based on the results of circular dichroism and denaturation studies, we show that the RNA polymerase undergoes subtle conformational changes upon the binding of RTP, although the interaction does not significantly modify the stability of the protein. Finally, although metal ions are required for catalytic activity, they are not required for the initial binding of RTP to the polymerase. Such quantitative analyses are of primary importance for the rational design of new ribavirin analogues of potential therapeutic value and provide crucial insights on the interaction between RTP and the HCV RNA polymerase.
Bougie
Isabelle
I
Département de Biochimie, Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada.
Bisaillon
Martin
M
D000255:Adenosine Triphosphate / Q000494:pharmacology; D001665:Binding Sites; D001667:Binding, Competitive; D002384:Catalysis; D002942:Circular Dichroism; D012321:DNA-Directed RNA Polymerases / Q000737:chemistry*; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D019791:Guanidine / Q000494:pharmacology; D016174:Hepacivirus / Q000201:enzymology*; D016898:Interferon-alpha / Q000737:chemistry; D007477:Ions; D007700:Kinetics; D008024:Ligands; D009711:Nucleotides / Q000737:chemistry*; D010766:Phosphorylation; D011485:Protein Binding; D012254:Ribavirin / Q000737:chemistry / Q000494:pharmacology*; D013050:Spectrometry, Fluorescence; D013053:Spectrophotometry; D013816:Thermodynamics; D013997:Time Factors
D016898:Interferon-alpha; D007477:Ions; D008024:Ligands; D009711:Nucleotides; D012254:Ribavirin; C037827:ribavirin 5'-triphosphate; D000255:Adenosine Triphosphate; D012321:DNA-Directed RNA Polymerases; D019791:Guanidine